Genmab — Oktober 2019
-
Aktien har lagt fint fra land i dag.

-
Køberne er insisterende.
-
Sukker, jeg har ikke hørt nyt om elo, men det har jo altid ligget der som alternativ (SLAMF7) i RRMM når cd38 ikke længere virker. Mere bekymrende er at isa nu er på vej i sc-udgave. Dog stadig langt bagud. https://clinicaltrials.gov/ct2/show/NCT04045795
-
PR siger: Richardson noted that isatuximab binds to a distinct epitope of CD38 from Darzalex, which could position the drug for use in cases when the latter fails. https://medcitynews.com/2019/06/sanofis-isatuximab-shines-in-myeloma-at-asco-but-where-will-it-fit-into-treatment/?rf=1
-
Regner vi med at næste kurstrigger er den 15. oktober?
-
En kurstrigger kan i sagens natur gå begge veje. Vi må se og heppe på E L's håb/spådom.
-
Yes E L, but I am rooting for your håb :
D -

-
7 gange så mange MM. Amy 50-80 år http://amyloidosis.org/facts/al/
-
Nu vi er ved isa. Ud over at de altså allerede har en sc-version i klinikken, så kører de ufortrødent på med isa+atezo i solide. https://www.clinicaltrials.gov/ct2/show/NCT03637764?term=isatuximab+atezolizumab&rank=1
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
I have to admit, after last weeks' discussion & confusion, it is more håb as spådom